Haemonetics Corporation is a global healthcare company that specializes in providing innovative blood management solutions
The company develops and manufactures a range of systems and products designed to optimize the collection, processing, and transfusion of blood and its components. Haemonetics focuses on enhancing blood safety and efficiency within healthcare settings, offering technologies that support blood donation and transfusion processes, as well as promoting the overall health of patients through effective blood management practices. Their commitment to improving patient outcomes and supporting healthcare providers makes them a key player in the field of healthcare technology.
HAEMONETICS CORP/MASS is a hidden gem, featuring undervaluation and robust fundamentals. NYSE:HAE showcases decent financial health and profitability, coupled with an attractive price.
Blood products company Haemonetics (NYSEHAE). fell short of the market’s revenue expectations in Q4 CY2024 as sales rose 3.7% year on year to $348.5 million. Its non-GAAP profit of $1.19 per share was 1.7% above analysts’ consensus estimates.
Analyst upgrades Haemonetics to Buy, believes company can reach high-20% operating margin goal by FY26 through product mix analysis. Price target set at $112.
Favorable earnings estimate revisions are key for a stock to move higher. Let’s examine a few highly ranked stocks, including Stride, Interactive Brokers, and Haemonetics.
